You just read:

New Data presented at European Respiratory Society (ERS) comparing the once-daily dual bronchodilator Ultibro® Breezhaler® to Advair* Diskus* further supports the efficacy of Ultibro® Breezhaler® in moderate to severe COPD patients

News provided by

Novartis Pharmaceuticals Canada Inc.

Sep 08, 2014, 08:00 ET